Leaflet TAPTIQOM 15mcg / 5mg / ml ophthalmic drops single dose solution


Indicated for: glaucoma; ocular hypertension

Substance: tafluprost + timolol (glaucoma agent + beta blocker)

ATC: S01ED51 (Sensory organs | Antiglaucoma preparations and miotics | Beta blocking agents)

This combination of tafluprost and timolol is used for the treatment of open-angle glaucoma and ocular hypertension. Tafluprost lowers intraocular pressure by increasing the outflow of aqueous humor, while timolol reduces the production of aqueous humor.

The medication is administered as eye drops, usually once daily, as directed by a doctor. It is important for patients to follow the usage instructions to achieve maximum efficacy.

Patients should be aware of potential side effects, such as eye irritation, redness, or a sensation of dryness in the eyes. It is important to inform the doctor of any unusual symptoms.

Common side effects include eye irritation, a burning or itching sensation, and gradual changes in iris color. In rare cases, allergic reactions, ocular inflammation, or a decrease in heart rate may occur. Patients should be informed of these risks before starting treatment.

General data about TAPTIQOM 15mcg / 5mg / ml

  • Substance: tafluprost + timolol
  • Date of last drug list: 01-05-2026
  • Commercial code: W68546001
  • Concentration: 15mcg / 5mg / ml
  • Pharmaceutical form: ophthalmic drops single dose solution
  • Packing volume: 0,3 ml
  • Product type: original
  • Price: 100.94 RON
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

  • Manufacturer: SANTEN OY - FINLANDA
  • Holder: SANTEN OY - FINLANDA
  • Number: 14245/2022/01
  • Shelf life: 3 years-after packaging for sale; 28 days-after the first opening a pungii protectoare

Pharmaceutical forms available for tafluprost + timolol